Authors
Latest:
Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMMThe discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.
Latest:
Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK InhibitorsDavid L. DeRemer, PharmD, BCOP, and Bently P. Doonan, MD, MS, share a perspective on ocular toxicities associated with MEK inhibition.
Latest:
General Lifestyle Recommendations for Receiving Talquetamab in Multiple MyelomaSamatha Shenoy, NP, MSN, highlighted lifestyle recommendations to help patients who are receiving talquetamab treatment for multiple myeloma.
Latest:
Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical CancerThe FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.
Latest:
Use of CAR T-cell Therapy in Earlier Lines in Relapsed Refractory Multiple MyelomaPanelists discuss how the use of CAR T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma could potentially improve long-term outcomes, considering factors such as patient selection, optimal timing, and the impact on subsequent treatment options.
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Between the Lines™ Podcast: Incorporating Real-World Evidence into Clinical Decisions in NSCLCLyudmila Bazhenova, MD, and Federico Albrecht, MD, detailed the importance of using real-world evidence to inform treatment for patients with EGFR-mutated non–small cell lung cancer.
Latest:
Psycho-Oncology and the Relevance of a Biopsychosocial Screening ProgramRoutine biopsychosocial screening of a patient with metastatic renal cell cancer at the Centro de Câncer de Brasília improved symptom management and shrunk costs for both the patient and her caregivers.
Latest:
Progressing From Disparity to Equity: Untangling the Complexities of Timely Care and the Rural Cancer ExperienceRichard L. Martin III, MD, MPH, and Stephen Schleicher, MD, MBA, share a perspective on rural cancer care.
Latest:
Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MMPanelists discuss recent clinical trial findings, including the PERSEUS, CASSIOPEIA, IsKia, and GMMG-HD7 studies, and how these evolving treatment strategies are shaping the approach to frontline therapy for patients with transplant-eligible multiple myeloma.
Latest:
Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous CarcinosarcomaThis study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.
Latest:
Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1ABSTRACT Advances in immuno-oncology over the last several years have led to FDA approvals of novel agents. As our understanding of immune response and its checkpoints has evolved, further advances have been made in treatment for several cancer types. To predict a response to immunotherapy, the initial biomarkers used were expression of the PD-1 receptor and PD-L1, as assessed by immunohistochemistry. More recently, predictive biomarkers have included microsatellite instability, DNA mismatch repair, and tumor mutational burden. Although these markers may be clinically relevant in predicting an immunotherapy response, cancer immunotherapy fails some patients. Improved understanding of the human immune system is necessary, as is a careful evaluation of the methods used to predict and assess response to Immuno-oncology treatments. With the application of therapeutic immune-modulating agents, more comprehensive assays, and associated bioinformatics tools to accurately assess the tumor microenvironment, we may better predict responses to immuno-oncology agents and the ever-increasing complexity of their clinical use.
Latest:
Highlighted Data Review of CAR-T in Early R/R MMPanelists discuss how early-line chimeric antigen receptor T-cell therapy studies, including recent data from trials of cilta-cel (Popat et al) and ide-cel (Ailawadhi et al), are showing promising results in patients with relapsed/refractory multiple myeloma, suggesting potential benefits of moving these treatments into earlier therapeutic settings.
Latest:
Patient Case 4: 50-Year-Old Woman Non-Smoker with Pleural MetastasesEstelamari Rodriguez, MD, MPH, presents a case of a 50-year-old African American woman, non-smoker, with pleural metastases; the panel discusses interstitial lung disease management, the use of antibody-drug conjugates, disease timing, and strategies for providing symptomatic relief, specifically considering drug holds if steroids only offer partial relief.
Latest:
Routine Breast Cancer Screening in Average-Risk Women Younger Than 50 Years: Current Paradigms Based on National GuidelinesApproximately 270,000 women are diagnosed with breast cancer each year in the United States alone. While there is consensus among national organizations including the US Preventive Services Task Force, the American Cancer Society, and the American College of Radiology that routine mammography screening should be performed in women 50 years and older, there is debate about the benefit-to-harm ratio of routine screening in average-risk women aged between 40 and 49 years. In this review, we examine risks and benefits of routine breast cancer screening starting at age 40 at the individual level, followed by evaluation of the role of advanced imaging techniques in screening women on a population level.
Latest:
Future Directions in mHSPC Management: An Evolving Treatment LandscapeKey opinion leaders in the field of prostate cancer close out their discussion by sharing excitement for future evolutions in the setting of hormone-sensitive disease management.
